219 related articles for article (PubMed ID: 9066045)
1. Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa.
Arya SC
Vaccine; 1997 Feb; 15(2):244. PubMed ID: 9066045
[No Abstract] [Full Text] [Related]
2. Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply.
Keddy KH; Klugman KP; Robbins JB
Vaccine; 1998; 16(9-10):871-2. PubMed ID: 9682329
[No Abstract] [Full Text] [Related]
3. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
4. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
5. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
Pulickal AS; Pollard AJ
Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
[No Abstract] [Full Text] [Related]
6. Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa.
Wandel G
Vaccine; 1997 Dec; 15(17-18):1815. PubMed ID: 9413086
[No Abstract] [Full Text] [Related]
7. A Salmonella typhi Vi conjugate vaccine.
Koul PA
N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
[No Abstract] [Full Text] [Related]
8. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers.
Azze RF; Rodríguez JC; Iniesta MG; Marchena XR; Alfonso VM; Padrón FT
Vaccine; 2003 Jun; 21(21-22):2758-60. PubMed ID: 12798615
[TBL] [Abstract][Full Text] [Related]
9. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
10. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
[TBL] [Abstract][Full Text] [Related]
11. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever.
Tacket CO; Levine MM; Robbins JB
Vaccine; 1988 Aug; 6(4):307-8. PubMed ID: 3188615
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
[TBL] [Abstract][Full Text] [Related]
13. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization.
Keddy KH; Klugman KP; Hansford CF; Blondeau C; Bouveret le Cam NN
Vaccine; 1999 Jan; 17(2):110-3. PubMed ID: 9987143
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
15. Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay.
Ahmadi H; Tabaraie B; Maleknia S; Shapouri R; Nejati M; Pour Mirza Gholi F; Hedayati M; Sadati M; Zahednia S; Sharifat Salmani A
J Med Microbiol; 2013 Feb; 62(Pt 2):283-286. PubMed ID: 23105026
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
[TBL] [Abstract][Full Text] [Related]
17. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
18. Vaccination against intracellular bacterial pathogens.
Pang T
Trends Microbiol; 1998 Nov; 6(11):433. PubMed ID: 9846359
[No Abstract] [Full Text] [Related]
19. Population impact of Vi capsular polysaccharide vaccine.
Khan MI; Ochiai RL; Clemens JD
Expert Rev Vaccines; 2010 May; 9(5):485-96. PubMed ID: 20450323
[TBL] [Abstract][Full Text] [Related]
20. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
Klugman KP; Gilbertson IT; Koornhof HJ; Robbins JB; Schneerson R; Schulz D; Cadoz M; Armand J
Lancet; 1987 Nov; 2(8569):1165-9. PubMed ID: 2890805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
